Novel oxytocin receptor agonists and antagonists: a patent review (2002 – 2013)

Bibliography

• Alfirevic Z, Kelly AJ, Dowswell T. Intravenous oxytocin alone for cervical ripening and induction of labour. Cochrane Database Syst Rev 2009;CD003246
   Google Scholar
• Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev 2001;81:629-83
   PubMed Web of Science ®Google Scholar
• Carson DS, Guastella AJ, Taylor ER, et al. A brief history of oxytocin and its role in modulating psychostimulant effects. J Psychopharmacol 2013;27:231-47
   PubMed Web of Science ®Google Scholar
• Bichet D, Bouvier M, Chini B, et al. Vasopressin and oxytocin receptors: OT receptor. IUPHAR database (IUPHAR-DB). 2013. Available from: http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=369 [Last accessed 14 May 2013]
   Google Scholar
• Busnelli M, Sauliere A, Manning M, et al. Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes. J Biol Chem 2012;287:3617-29
   PubMed Web of Science ®Google Scholar
• Kenakin T, Christopoulos A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 2013;12:205-16
   PubMed Web of Science ®Google Scholar
• Yamasue H, Yee JR, Hurlemann R, et al. Integrative approaches utilizing oxytocin to enhance prosocial behavior: from animal and human social behavior to autistic social dysfunction. J Neurosci 2012;32:14109-17
   PubMed Web of Science ®Google Scholar
• Wallis M. Molecular evolution of the neurohypophysial hormone precursors in mammals: comparative genomics reveals novel mammalian oxytocin and vasopressin analogues. Gen Comp Endocrinol 2012;179:313-18
   PubMed Web of Science ®Google Scholar
• Vaccari C, Lolait SJ, Ostrowski NL. Comparative distribution of vasopressin V1b and oxytocin receptor messenger ribonucleic acids in brain. Endocrinology 1998;139:5015-33
   PubMed Web of Science ®Google Scholar
• Yoshimura R, Kiyama H, Kimura T, et al. Localization of oxytocin receptor messenger ribonucleic acid in the rat brain. Endocrinology 1993;133:1239-46
   PubMed Web of Science ®Google Scholar
• Nishimori K, Takayanagi Y, Yoshida M, et al. New aspects of oxytocin receptor function revealed by knockout mice: sociosexual behaviour and control of energy balance. Prog Brain Res 2008;170:79-90
   PubMed Web of Science ®Google Scholar
• Lee HJ, Caldwell HK, Macbeth AH, et al. A conditional knockout mouse line of the oxytocin receptor. Endocrinology 2008;149:3256-63
   PubMed Web of Science ®Google Scholar
• Macbeth AH, Stepp JE, Lee HJ, et al. Normal maternal behavior, but increased pup mortality, in conditional oxytocin receptor knockout females. Behav Neurosci 2010;124:677-85
   PubMed Web of Science ®Google Scholar
• Dhakar MB, Rich ME, Reno EL, et al. Heightened aggressive behavior in mice with lifelong versus postweaning knockout of the oxytocin receptor. Horm Behav 2012;62:86-92
   PubMed Web of Science ®Google Scholar
• Pobbe RL, Pearson BL, Defensor EB, et al. Oxytocin receptor knockout mice display deficits in the expression of autism-related behaviors. Horm Behav 2012;61:436-44
   PubMed Web of Science ®Google Scholar
• Lee HJ, Caldwell HK, Macbeth AH, et al. Behavioural studies using temporal and spatial inactivation of the oxytocin receptor. Prog Brain Res 2008;170:73-7
   PubMed Web of Science ®Google Scholar
• Oxytocin agonist. US2004235753A1; 2004
   Google Scholar
• Aron C, Simon P, Larousse C, et al. Evaluation of a rapid technique for detecting minor tranquilizers. Neuropharmacology 1971;10:459-69
   PubMed Web of Science ®Google Scholar
• Braff D, Stone C, Callaway E, et al. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 1978;15:339-43
   PubMed Web of Science ®Google Scholar
• Wyeth Corp. Methods of treatment using oxytocin receptor agonists. US20070117794A1; 2007
   Google Scholar
• Applied Research Systems ARS Holding N.V. Pyrrolidine oxadiazole- and thiadlazole oxime derivatives being oxytocin receptor antagonist. US2006229343A1; 2006
   Google Scholar
• Pfizer, Inc. Substituted triazole derivatives as oxytocin antagonists. US2010222365A1; 2010
   Google Scholar
• Ferring BV. Piperazines as oxytocin agonists. US2007197608A1; 2007
   Google Scholar
• Glaxo Group Ltd. Novel compounds. US2012202811A1; 2012
   Google Scholar
• Glaxo Group Ltd. Piperazinediones as oxytocin receptor antagonists. US2007254888A1; 2007
   Google Scholar
• Oxytocin receptor antagonists and their use for the treatment of pulmonary related diseases. US20100260675A1; 2010
   Google Scholar
• Universite de Geneve. New uses of oxytocin-like molecules and related methods. US20130085100A1; 2013
   Google Scholar
• University of North Carolina at Chapel Hill. Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders. US20130085106A1; 2013
   Google Scholar
• Cytotoxic or radioactive conjugates able to bind to oxytocin receptors. WO2002098447A1; 2002
   Google Scholar
• Hunter DJ, Schulz P, Wassenaar W. Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus. Clin Pharmacol Ther 1992;52:60-7
   PubMed Web of Science ®Google Scholar
• Bekeova E, Krajnicakova M, Hendrichovsky V, et al. The effect of repeated administration of carbetocin (Depotocin, Spofa) in the first days postpartum on levels of thyroxine, triiodothyronine, 17 beta-estradiol, progesterone and on fertilization. Vet Med (Praha) 1992;37:393-404
   PubMedGoogle Scholar
• Su LL, Chong YS, Samuel M. Carbetocin for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2012;4:CD005457
   PubMed Web of Science ®Google Scholar
• Ortiz-Gomez JR, Morillas-Ramirez F, Fornet-Ruiz I, et al. Clinical and pharmacological study of the efficacy of carbetocin in elective caesareans compared to low and usual doses of oxytocin. Rev Esp Anestesiol Reanim 2013;60:7-15
   PubMedGoogle Scholar
• Feifel D, Shilling PD, Belcher AM. The effects of oxytocin and its analog, carbetocin, on genetic deficits in sensorimotor gating. Eur Neuropsychopharmacol 2012;22:374-8
   PubMed Web of Science ®Google Scholar
• Steckler D, Naidoo V, Gerber D, et al. Ex vivo influence of carbetocin on equine myometrial muscles and comparison with oxytocin. Theriogenology 2012;78:502-9
   PubMed Web of Science ®Google Scholar
• De Bonis M, Torricelli M, Leoni L, et al. Carbetocin versus oxytocin after caesarean section: similar efficacy but reduced pain perception in women with high risk of postpartum haemorrhage. J Matern Fetal Neonatal Med 2012;25:732-5
   PubMed Web of Science ®Google Scholar
• Moertl MG, Friedrich S, Kraschl J, et al. Haemodynamic effects of carbetocin and oxytocin given as intravenous bolus on women undergoing caesarean delivery: a randomised trial. BJOG 2011;118:1349-56
   PubMed Web of Science ®Google Scholar
• Page GH. Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: the results of a double-blind randomised trial. BJOG 2010;117:1665; author reply 65-6
   PubMedGoogle Scholar
• Lowbridge J, Manning M, Haldar J, et al. [1-(L-2-hydroxy-3-mercaptopropanoic acid)] analogues of arginine-vasopressin, [8-D-arginine]vasopressin, and [4-valine,8-D-arginine]vasopressin. J Med Chem 1977;20:1173-6
   PubMed Web of Science ®Google Scholar
• Sternadel Z, Gerkowicz J. Use of deaminooxytocin (Sandopart) in the prevention and treatment of puerperal mastitis. Ginekol Pol 1979;50:413-16
   PubMedGoogle Scholar
• Chini B, Mouillac B, Balestre MN, et al. Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin. FEBS Lett 1996;397:201-6
   PubMed Web of Science ®Google Scholar
• Chini B, Mouillac B, Ala Y, et al. Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. EMBO J 1995;14:2176-82
   PubMed Web of Science ®Google Scholar
• Jasper JR, Harrell CM, O'Brien JA, et al. Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. Life Sci 1995;57:2253-61
   PubMed Web of Science ®Google Scholar
• Fragiadaki M, Magafa V, Borovickova L, et al. Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem 2007;42:799-806
   PubMed Web of Science ®Google Scholar
• Breton C, Chellil H, Kabbaj-Benmansour M, et al. Direct identification of human oxytocin receptor-binding domains using a photoactivatable cyclic peptide antagonist: comparison with the human V1a vasopressin receptor. J Biol Chem 2001;276:26931-41
   PubMed Web of Science ®Google Scholar
• Griffante C, Green A, Curcuruto O, et al. Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist. Br J Pharmacol 2005;146:744-51
   PubMed Web of Science ®Google Scholar
• Ferring B.V. Oxytocin analogues. WO2009122285; 2009
   Google Scholar
• Wisniewski K, Galyean R, Schteingart C, et al. Synthesis and in vitro characterization of new potent and selective oxytocin receptor agonist. In: Lebl M, Meldal M, Knud J, et al. editors. Peptides 2010. Proc of the 31st European Peptide Symposium. Society TEP San Diego: 2010. p. 306-7
   Google Scholar
• Akerlund M. Targeting the oxytocin receptor to relax the myometrium. Expert Opin Ther Targets 2006;10:423-7
   PubMed Web of Science ®Google Scholar
• Quattropani A, Dorbais J, Covini D, et al. Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists. J Med Chem 2005;48:7882-905
   PubMed Web of Science ®Google Scholar
• Serradeil-Le Gal C, Valette G, Foulon L, et al. SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro -1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor. J Pharmacol Exp Ther 2004;309:414-24
   PubMed Web of Science ®Google Scholar
• Bell IM, Erb JM, Freidinger RM, et al. Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines. J Med Chem 1998;41:2146-63
   PubMed Web of Science ®Google Scholar
• Cirillo R, Gillio Tos E, Schwarz MK, et al. Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor. J Pharmacol Exp Ther 2003;306:253-61
   PubMed Web of Science ®Google Scholar
• Pettibone DJ, Clineschmidt BV, Anderson PS, et al. A structurally unique, potent, and selective oxytocin antagonist derived from Streptomyces silvensis. Endocrinology 1989;125:217-22
   PubMed Web of Science ®Google Scholar
• Evans BE, Leighton JL, Rittle KE, et al. Orally active, nonpeptide oxytocin antagonists. J Med Chem 1992;35:3919-27
   PubMed Web of Science ®Google Scholar
• Weyth Corp. Novel 10-cyclohexenyl-phenyl pyrrolobenzodiazepine-3-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists. MXPA03009337A; WO02083682A1; 2002
   Google Scholar
• Weyth Corp. Tricyclic diazepines as tocolytic oxytocin receptor antagonists. WO02083678A1; 2002
   Google Scholar
• Wyeth Corp. Novel pyridine- and cyclohexenyl-comprising pyrrolobenzodiazepi ne-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists. WO02083684A1; 2002
   Google Scholar
• Wyeth Corp. Novel hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists. CA2443564A1; WO02083679; 2002
   Google Scholar
• Wyeth Corp. Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists. US2003055047A1; 2003
   Google Scholar
• Wyeth Corp. Novel pyrido cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists. US2003055046A1; 2003
   Google Scholar
• Wyeth Corp. Novel cyclohexenylphenyl carboxamides tocolytic oxytocin receptor antagonists. US20030027815A1; 2003
   Google Scholar
• Wyeth Corp. Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists. US2003018026A1; 2003
   Google Scholar
• Wyeth Corp. Novel tricyclic diazepines tocolytic oxytocin receptor antagonists. US2003008863A1; 2003
   Google Scholar
• Wyeth Corp. Novel cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists. US2003004159A1; 2003
   Google Scholar
• Wyeth Corp. Novel cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators. US20020198196A1; 2002
   Google Scholar
• Wyeth Corp. Hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists. US6977254B2; 2005
   Google Scholar
• Wyeth Corp. Novel 10-cyclohexenyl-phenyl pyrrolobenzodiazepine-3-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists. CA2443556; WO02083682; 2002
   Google Scholar
• Applied Research Systems ARS Holding N.V. Pyrrolidine oxadiazole- and thiadlazole oxime derivatives. WO02102799A2; 2002
   Google Scholar
• Applied Research Systems ARS Holding N.V. Pyrrolidine oxadiazole- and thiadlazole derivatives. US20040220238A1; 2004
   Google Scholar
• Glaxo Group Ltd. Substituted diketopiperazines as oxytocin receptor antagonists. US2009186867A1; 2009
   Google Scholar
• Koninklijke Philips Electronics. Substituted diketopiperazines as oxytocin receptor antagonists. US20070185162A1; 2007
   Google Scholar
• Substituted diketopiperazines as oxytocin receptor antagonists. US20050148572A1; 2005
   Google Scholar
• Glaxo Group Ltd. Piperazinediones as oxytocin receptor antagonists. US7550462B2; 2009
   Google Scholar
• Glaxo Group Ltd. Substituted diketopiperazines as oxytocin antagonists. US201301301338A1; 2013
   Google Scholar
• Glaxo Group Ltd. Substituted diketopiperazines and their use as oxytocin antagonists. US20130102783A1; 2013
   Google Scholar
• 1-6-Substituted (3R,6R)-3-(2,3-Dihydro-1H-Inden-2-Yl)-2,5-Piperazinedione Derivatives as Oxytocin Receptor Antagonists For the Treatment of Preterm Labour, Dysmenorrhea and Endometriosis. US20080242666A1; 2008
   Google Scholar
• Glaxo Group Ltd. 1-6-Substituted (3R,6R)-3-(2,3-Dihydro-1H-Inden-2-Yl)-2,5-Piperazinedione Derivatives as Oxytocin Receptor Antagonists For the Treatment of Preterm Labour, Dysmenorrhea and Endometriosis. WO2006067462A1; 2006
   Google Scholar
• Borthwick AD, Liddle J. Methods and principles in medicinal chemistry: protein-protein interactions in drug discovery. Wiley-VCH; Weinheim: 2013
   Google Scholar
• Manning M, Misicka A, Olma A, et al. Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol 2012;24:609-28
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis FR. Novel indolin-2-one derivatives, their preparation and the pharmaceutical compositions comprising them. US2007203184A1; 2007
   Google Scholar
• Sanofi-Synthelabo. Indolin-2-one derivatives, preparation and their use as oxytocin receptor ligands. US6673790B1; 2004
   Google Scholar
• Sanofi-Aventis FR. Indolin-2-one derivatives, method for obtaining thereof and use as ligands of oxytocin receptor. UA73163C2; 2005
   Google Scholar
• Sanofi-Synthelabo. 3-spiro-indolin-2-one derivatives as vasopressin and/or oxytocin receptor ligands. P2001302631A; 2001
   Google Scholar
• Sanofi-Synthelabo. 3-spiro-indolin-2-one derivatives as vasopressin and/or oxytocin receptor ligands. US5994350A; 1999
   Google Scholar
• Pfizer, Inc. Substituted triazole derivatives as oxytocin antagonists. US20130137671A1; 2013
   Google Scholar
• Substituted triazole derivatives as oxytocin antagonists. US2008167323A1; 2008
   Google Scholar
• Substituted triazole derivatives as oxytocin antagonists. US2008214622A1; 2008
   Google Scholar
• Ferring BV. Benzamide derivayives as oxytocin agonists and vasopressin antagonists. MXPA05008601A; 2004
   Google Scholar
• Ring RH, Schechter LE, Leonard SK, et al. Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology 2010;58:69-77
   PubMed Web of Science ®Google Scholar
• Hicks C, Jorgensen W, Brown C, et al. The nonpeptide oxytocin receptor agonist WAY 267,464: receptor-binding profile, prosocial effects and distribution of c-Fos expression in adolescent rats. J Neuroendocrinol 2012;24:1012-29
   PubMed Web of Science ®Google Scholar
• Ferring international center SA. Oxytocin receptor agonist. US20120214733A1; 2012
   Google Scholar
• Centocor, Inc.; Johnson & Johnson Research PTY Ltd. Oxytocin receptor antagonists and their use for the treatment of pulmonary related diseases. WO2006063168A2; 2006
   Google Scholar
• Abbott GmbH & Co. KG. Substituted oxindole derivatives and their use as Vasopressin and/or Oxytocin receptor ligands. US2009318406A1; 2009
   Google Scholar
• Danalache BA, Gutkowska J, Slusarz MJ, et al. Oxytocin-Gly-Lys-Arg: a novel cardiomyogenic peptide. PLoS One 2010;5:e13643
   Web of Science ®Google Scholar
• Alizadeh AM, Faghihi M, Sadeghipour HR, et al. Oxytocin protects rat heart against ischemia-reperfusion injury via pathway involving mitochondrial ATP-dependent potassium channel. Peptides 2010;31:1341-5
   PubMed Web of Science ®Google Scholar
• Li C, Wang W, Summer SN, et al. Molecular mechanisms of antidiuretic effect of oxytocin. J Am Soc Nephrol 2008;19:225-32
   PubMed Web of Science ®Google Scholar
• Tamma R, Colaianni G, Zhu LL, et al. Oxytocin is an anabolic bone hormone. Proc Natl Acad Sci USA 2009;106:7149-54
   PubMed Web of Science ®Google Scholar
• Eckertova M, Ondrejcakova M, Krskova K, et al. Subchronic treatment of rats with oxytocin results in improved adipocyte differentiation and increased gene expression of factors involved in adipogenesis. Br J Pharmacol 2011;162:452-63
   PubMed Web of Science ®Google Scholar
• Zink CF, Meyer-Lindenberg A. Human neuroimaging of oxytocin and vasopressin in social cognition. Horm Behav 2012;61:400-9
   PubMed Web of Science ®Google Scholar
• McGregor IS, Bowen MT. Breaking the loop: oxytocin as a potential treatment for drug addiction. Horm Behav 2012;61:331-9
   PubMed Web of Science ®Google Scholar
• Ayers LW, Missig G, Schulkin J, et al. Oxytocin reduces background anxiety in a fear-potentiated startle paradigm: peripheral vs central administration. Neuropsychopharmacology 2011;36:2488-97
   PubMed Web of Science ®Google Scholar
• Landgraf R, Neumann ID. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front Neuroendocrinol 2004;25:150-76
   PubMed Web of Science ®Google Scholar
• Neumann ID, Landgraf R. Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. Trends Neurosci 2012;35:649-59
   PubMed Web of Science ®Google Scholar
• Loup F, Tribollet E, Dubois-Dauphin M, et al. Localization of high-affinity binding sites for oxytocin and vasopressin in the human brain. An autoradiographic study. Brain Res 1991;555:220-32
   PubMed Web of Science ®Google Scholar
• Miller G. Neuroscience. The promise and perils of oxytocin. Science 2013;339:267-9
   PubMed Web of Science ®Google Scholar
• Weyth Corp. Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists. US7691848B2; 2010
   Google Scholar
• Emmons SW. Neuroscience. The mood of a worm. Science 2012;338:475-6
   PubMed Web of Science ®Google Scholar
• Garrison JL, Macosko EZ, Bernstein S, et al. Oxytocin/vasopressin-related peptides have an ancient role in reproductive behavior. Science 2012;338:540-3
   PubMed Web of Science ®Google Scholar
• Beets I, Janssen T, Meelkop E, et al. Vasopressin/oxytocin-related signaling regulates gustatory associative learning in C. elegans. Science 2012;338:543-5
   PubMed Web of Science ®Google Scholar